{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:56:12Z","timestamp":1788216972797,"version":"build-2803163510"},"reference-count":62,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.5582\/ddt.2025.01043","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T22:07:13Z","timestamp":1751148433000},"page":"160-173","source":"Crossref","is-referenced-by-count":2,"title":["Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system"],"prefix":"10.5582","volume":"19","author":[{"given":"Qian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Center, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panwei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cao F, Pan HF, Hou S. A novel metric of autoimmune disease burden and its estimated incidence across different stages in life cycle of women. Autoimmun Rev. 2024; 23:103671.","DOI":"10.1016\/j.autrev.2024.103671"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. van Loo G, Bertrand MJM. Death by TNF: a road to inflammation. Nat Rev Immunol. 2023; 23:289-303.","DOI":"10.1038\/s41577-022-00792-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jenkins C, Roberts J, Wilson R, MacLean MA, Shilito J, Walker JJ. Evidence of a T(H) 1 type response associated with recurrent miscarriage. Fertil Steril. 2000; 73:1206-1208.","DOI":"10.1016\/S0015-0282(00)00517-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Romanowska-Prochnicka K, Felis-Giemza A, Olesinska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The Role of TNF-alpha and Anti-TNF-alpha Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci. 2021; 22:2922.","DOI":"10.3390\/ijms22062922"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Liu M, Zhen X, Song H, Chen J, Sun X, Li X, Zhou J, Yan G, Ding L, Sun H. Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1\/Th2\/Treg paradigm in patients with unexplained recurrent miscarriage. Reprod Biol Endocrinol. 2017; 15:95.","DOI":"10.1186\/s12958-017-0315-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. 2011; 1221:80-87.","DOI":"10.1111\/j.1749-6632.2010.05938.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Spence T, Allsopp PJ, Yeates AJ, Mulhern MS, Strain JJ, McSorley EM. Maternal Serum Cytokine Concentrations in Healthy Pregnancy and Preeclampsia. J Pregnancy. 2021; 2021:6649608.","DOI":"10.1155\/2021\/6649608"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Guinn D, Kratz K, Baisden K, Ridge S, McClymont S, Fletcher EP, Johnson T, Wang YM. On placental and lactational transfer of IgG-based therapeutic proteins - Current understanding and knowledge gaps from a clinical pharmacology perspective. Clin Transl Sci. 2024; 17:e70049.","DOI":"10.1111\/cts.70049"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dai FF, Hu M, Zhang YW, Zhu RH, Chen LP, Li ZD, Huang YJ, Hu W, Cheng YX. TNF-alpha\/anti-TNF-alpha drugs and its effect on pregnancy outcomes. Expert Rev Mol Med. 2022; 24:e26.","DOI":"10.1017\/erm.2022.18"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis\/psoriatic arthritis: an updated review. Am J Clin Dermatol. 2007; 8:143-155.","DOI":"10.2165\/00128071-200708030-00002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, <i>et al<\/i>. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75:795-810.","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chopra CR, Sharma M, Gill MS, Del Balso V, Sakka N, Abu-Hilal M. Maternal, Fetal, and Labour Outcomes of Dupilumab Use for Atopic Dermatitis During Pregnancy: A Systematic Review. J Cutan Med Surg. 2025; 29:51-55.","DOI":"10.1177\/12034754241290806"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Watson N, Wu K, Farr P, Reynolds NJ, Hampton PJ. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. Br J Dermatol. 2019; 180:195-196.","DOI":"10.1111\/bjd.17086"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gorodensky JH, Bernatsky S, Afif W, Filion KB, Vinet E. Ustekinumab Safety in Pregnancy: A Comprehensive Review. Arthritis Care Res (Hoboken). 2023; 75:930-935.","DOI":"10.1002\/acr.24813"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wise J. Rheumatic diseases should be actively treated in pregnancy, new guidelines say. BMJ. 2016; 532:i312.","DOI":"10.1136\/bmj.i312"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Seow CH, Ma C. Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy. Aliment Pharmacol Ther. 2021; 53:450-451.","DOI":"10.1111\/apt.16207"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kachikis A, Englund JA. Maternal immunization: Optimizing protection for the mother and infant. J Infect. 2016; 72 Suppl:S83-90.","DOI":"10.1016\/j.jinf.2016.04.027"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Joshi A, Gawey L, Saadi C, Naidoo P, Rick JW, Park SY, Cogen AL, Daveluy SD, Hsiao JL, Shi VY. Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database. J Am Acad Dermatol. 2025; 92:1434-1435.","DOI":"10.1016\/j.jaad.2025.02.031"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sakai T, Mori C, Ohtsu F. Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. Front Pharmacol. 2022; 13:1063625.","DOI":"10.3389\/fphar.2022.1063625"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zhou J, Wei Z, Lai W, Liu M, Wu X. The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2025; 91:1272-1280.","DOI":"10.1111\/bcp.16354"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Xu H, Xu N, Wang Y, Zou H, Wu S. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024; 15:1442002.","DOI":"10.3389\/fphar.2024.1442002"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Liu Y, Liu Y, Fan R, Kehriman N, Zhang X, Zhao B, Huang L. Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis. Eur J Med Res. 2023; 28:95.","DOI":"10.1186\/s40001-023-01048-z"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Liu H, Zou Y, Zhang Q, Zhao J, Wu J, Li X, Cheng Y, Wei H, Li H, Cao S. Pharmacovigilance insights into medication-induced risk of dural arteriovenous fistula. Int J Surg. 2025; 111:1847-1859.","DOI":"10.1097\/JS9.0000000000002214"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013; 22:57-69.","DOI":"10.1177\/0962280211403604"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Liu J, Xue L, Zeng F, Liu Y, Zhu Y, Zhou J, Zhang J, Chen H. Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database. Eur Child Adolesc Psychiatry. 2025. doi: 10.1007\/s00787-025-02694-w.","DOI":"10.1007\/s00787-025-02694-w"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022; 10:996179.","DOI":"10.3389\/fpubh.2022.996179"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Zhang S , Yan MM, Zhao H, Qiu XY, Zhu D. Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system. Front Pharmacol. 2024; 15:1445324.","DOI":"10.3389\/fphar.2024.1445324"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Inaba I, Kondo Y, Iwasaki S, Tsuruhashi S, Akaishi A, Morita K, Oniki K, Saruwatari J, Ishitsuka Y, Irie T. Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin-Angiotensin System Inhibitors: The Detection of Signals of Drug-Drug Interactions. Front Pharmacol. 2019; 10:874.","DOI":"10.3389\/fphar.2019.00874"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Weber-Schoendorfer C, Diav-Citrin O. Methotrexate in pregnancy: still many unanswered questions. RMD Open. 2023; 9:e002899.","DOI":"10.1136\/rmdopen-2022-002899"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Bulletti C, Flamigni C, Giacomucci E. Reproductive failure due to spontaneous abortion and recurrent miscarriage. Hum Reprod Update. 1996; 2:118-136.","DOI":"10.1093\/humupd\/2.2.118"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lynch MM, Amoozegar JB, McClure EM, Squiers LB, Broussard CS, Lind JN, Polen KN, Frey MT, Gilboa SM, Biermann J. Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists. Qual Health Res. 2017; 27:2071-2080.","DOI":"10.1177\/1049732317732027"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022; 18:591-602.","DOI":"10.1038\/s41584-022-00827-y"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Zhang Z, Gao X, Liu S, Wang Q, Wang Y, Hou S, Wang J, Zhang Y. Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20-54 years from 1990 to 2021. Sci Rep. 2025; 15:10736.","DOI":"10.1038\/s41598-025-92150-1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ali RA. The positive influences of increasing age at diagnosis of inflammatory bowel disease on disease prognostication in asian perspective. Intest Res. 2015; 13:4-5.","DOI":"10.5217\/ir.2015.13.1.4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Quezada SM, Steinberger EK, Cross RK. Association of age at diagnosis and Crohn&apos;s disease phenotype. Age Ageing. 2013; 42:102-106.","DOI":"10.1093\/ageing\/afs107"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018; 4:1.","DOI":"10.1038\/s41572-018-0001-z"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020; 100:adv00160.","DOI":"10.2340\/00015555-3510"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM, Global Psoriasis A. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol. 2021; 184:243-258.","DOI":"10.1111\/bjd.19169"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018; 30:137-143.","DOI":"10.1097\/BOR.0000000000000475"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Shakuntulla F, Chiarella SE. Safety of Biologics for Atopic Diseases During Pregnancy. J Allergy Clin Immunol Pract. 2022; 10:3149-3155.","DOI":"10.1016\/j.jaip.2022.08.013"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn&apos;s disease. Lancet. 2017; 389:1741-1755.","DOI":"10.1016\/S0140-6736(16)31711-1"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Kalagiri RR, Carder T, Choudhury S, Vora N, Ballard AR, Govande V, Drever N, Beeram MR, Uddin MN. Inflammation in Complicated Pregnancy and Its Outcome. Am J Perinatol. 2016; 33:1337-1356.","DOI":"10.1055\/s-0036-1582397"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Joswig A, Gabriel HD, Kibschull M, Winterhager E. Apoptosis in uterine epithelium and decidua in response to implantation: evidence for two different pathways. Reprod Biol Endocrinol. 2003; 1:44.","DOI":"10.1186\/1477-7827-1-44"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Calleja-Agius J, Jauniaux E, Pizzey AR, Muttukrishna S. Investigation of systemic inflammatory response in first trimester pregnancy failure. Hum Reprod. 2012; 27:349-357.","DOI":"10.1093\/humrep\/der402"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther. 2017; 30. doi: 10.1111\/dth.12454.","DOI":"10.1111\/dth.12454"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Zhong Z, Wang Y, Wang G, Zhou F. Case Report: TNF-Alpha Inhibitors to Rescue Pregnancy in Women With Potential Pregnancy Loss: A Report of Ten Cases. Front Immunol. 2022; 13:900537.","DOI":"10.3389\/fimmu.2022.900537"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf. 2017; 26:1109-1118.","DOI":"10.1002\/pds.4261"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Meyer A, Miranda S, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025; 23:144-153 e122.","DOI":"10.1016\/j.cgh.2023.12.029"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Sanchez-Garcia V, Hernandez-Quiles R, de-Miguel-Balsa E, Gimenez-Richarte A, Ramos-Rincon JM, Belinchon-Romero I. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023; 37:1971-1990.","DOI":"10.1111\/jdv.19238"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Avallone G, Cavallo F, Tancredi A, <i>et al<\/i>. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2024; 38:1799-1808.","DOI":"10.1111\/jdv.19794"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Tektonidou MG, Andreoli L, Limper M, <i>et al<\/i>. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78:1296-1304.","DOI":"10.1136\/annrheumdis-2019-215213"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011; 117:6948-6951.","DOI":"10.1182\/blood-2011-02-339234"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Meng L, Huang J, Qiu F, Shan X, Chen L, Sun S, Wang Y, Yang J. Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. Front Pharmacol. 2022; 13:757415.","DOI":"10.3389\/fphar.2022.757415"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Obstetrical and neonatal outcome in pregnant patients with rheumatic disease. Scand J Rheumatol Suppl. 1998; 107:109-112.","DOI":"10.1080\/03009742.1998.11720781"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Broms G, Haerskjold A, Granath F, Kieler H, Pedersen L, Berglind IA. Effect of Maternal Psoriasis on Pregnancy and Birth Outcomes: A Population-based Cohort Study from Denmark and Sweden. Acta Derm Venereol. 2018; 98:728-734.","DOI":"10.2340\/00015555-2923"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol. 2016; 175:464-472.","DOI":"10.1111\/bjd.14547"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Giovannopoulou E, Gkasdaris G, Kapetanakis S, Kontomanolis E. Ankylosing Spondylitis and Pregnancy: A Literature Review. Curr Rheumatol Rev. 2017; 13:162-169.","DOI":"10.2174\/1573397113666170317114857"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Sanchez-Garcia V, De-Miguel-Balsa E, Ramos-Rincon JM, Belinchon-Romero I. Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2025; 105:adv41307.","DOI":"10.2340\/actadv.v105.41307"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Bandoli G, Johnson DL, Jones KL, Lopez Jiminez J, Salas E, Mirrasoul N, Van Voorhees AS, Chambers CD. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol. 2010; 163:334-339.","DOI":"10.1111\/j.1365-2133.2010.09899.x"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Pedersen N, Bortoli A, Duricova D, <i>et al<\/i>. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013; 38:501-512.","DOI":"10.1111\/apt.12412"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014; 20:1091-1098.","DOI":"10.1097\/MIB.0000000000000060"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Magnus MC, Morken NH, Wensaas KA, Wilcox AJ, Haberg SE. Risk of miscarriage in women with chronic diseases in Norway: A registry linkage study. PLoS Med. 2021; 18:e1003603.","DOI":"10.1371\/journal.pmed.1003603"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/3\/19_2025.01043\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:49:35Z","timestamp":1751690975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/3\/19_2025.01043\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01043","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"2025.01043"}}